BACKGROUND & AIMS: Induction of oral immune tolerance (OT) blocks proinflammatory responses to orally administered antigens and might be used to treat autoimmune conditions. We investigated whether gut-tropic T cells that express the integrin α4β7 and the chemokine receptor CCR9 are required for OT. METHODS: Skin delayed-type hypersensitivity and experimental autoimmune encephalomyelitis were used to monitor OT in mice. To assess the role of receptors that mediate localization of lymphocytes to the gut (gut-homing receptors) in induction of OT, we studied CCR9(-/-) and β7(-/-) mice and also blocked the α4β7 ligand MAdCAM-1 in wild-type mice. We used DEREG and Scurfy mice to assess the role of Foxp3(+) regulatory T cells (Treg) and IL-10(-/-) and IL-10Rβ(-/-) mice to examine the role of interleukin (IL)-10 in induction of OT. RESULTS: OT could not be induced in CCR9(-/-) or β7(-/-) mice, or when MAdCAM-1 was blocked in wild-type mice, indicating that gut-homing receptors are required for oral tolerization. Consistent with the role of all-trans retinoic acid in inducing gut-homing T cells, OT could not be induced in mice depleted of vitamin A. OT was rescued in CCR9(-/-) mice following adoptive transfer of wild-type T cells, but not CCR9(-/-) or β7(-/-) T cells. Gut-homing T cells are therefore necessary and sufficient to induce OT. Wild-type Treg and IL-10 were required to restore OT to CCR9(-/-) mice, indicating that homing and functional differentiation of IL-10-producing Treg in the gut is required for OT. Conversely, transfer of CCR9(-/-) or β7(-/-) T cells to wild-type mice partially inhibited OT. CONCLUSIONS: Expression of CCR9 and α4β7 on T cells and their subsequent localization to the gut is required for induction of OT in mice. Therapies designed to block gut-homing receptors might, under some conditions, interfere with normal tolerogenic mechanisms in the intestinal mucosa.
BACKGROUND & AIMS: Induction of oral immune tolerance (OT) blocks proinflammatory responses to orally administered antigens and might be used to treat autoimmune conditions. We investigated whether gut-tropic T cells that express the integrin α4β7 and the chemokine receptor CCR9 are required for OT. METHODS: Skin delayed-type hypersensitivity and experimental autoimmune encephalomyelitis were used to monitor OT in mice. To assess the role of receptors that mediate localization of lymphocytes to the gut (gut-homing receptors) in induction of OT, we studied CCR9(-/-) and β7(-/-) mice and also blocked the α4β7 ligand MAdCAM-1 in wild-type mice. We used DEREG and Scurfy mice to assess the role of Foxp3(+) regulatory T cells (Treg) and IL-10(-/-) and IL-10Rβ(-/-) mice to examine the role of interleukin (IL)-10 in induction of OT. RESULTS:OT could not be induced in CCR9(-/-) or β7(-/-) mice, or when MAdCAM-1 was blocked in wild-type mice, indicating that gut-homing receptors are required for oral tolerization. Consistent with the role of all-trans retinoic acid in inducing gut-homing T cells, OT could not be induced in mice depleted of vitamin A. OT was rescued in CCR9(-/-) mice following adoptive transfer of wild-type T cells, but not CCR9(-/-) or β7(-/-) T cells. Gut-homing T cells are therefore necessary and sufficient to induce OT. Wild-type Treg and IL-10 were required to restore OT to CCR9(-/-) mice, indicating that homing and functional differentiation of IL-10-producing Treg in the gut is required for OT. Conversely, transfer of CCR9(-/-) or β7(-/-) T cells to wild-type mice partially inhibited OT. CONCLUSIONS: Expression of CCR9 and α4β7 on T cells and their subsequent localization to the gut is required for induction of OT in mice. Therapies designed to block gut-homing receptors might, under some conditions, interfere with normal tolerogenic mechanisms in the intestinal mucosa.
Authors: L V Rizzo; R A Morawetz; N E Miller-Rivero; R Choi; B Wiggert; C C Chan; H C Morse; R B Nussenblatt; R R Caspi Journal: J Immunol Date: 1999-03-01 Impact factor: 5.422
Authors: Sheila M O'Byrne; Nuttaporn Wongsiriroj; Jenny Libien; Silke Vogel; Ira J Goldberg; Wolfgang Baehr; Krzysztof Palczewski; William S Blaner Journal: J Biol Chem Date: 2005-08-22 Impact factor: 5.157
Authors: Meike Wendland; Niklas Czeloth; Nicolas Mach; Bernard Malissen; Elisabeth Kremmer; Oliver Pabst; Reinhold Förster Journal: Proc Natl Acad Sci U S A Date: 2007-04-02 Impact factor: 11.205
Authors: Holm H Uhlig; Janine Coombes; Christian Mottet; Ana Izcue; Claire Thompson; Andrea Fanger; Andrea Tannapfel; Jason D Fontenot; Fred Ramsdell; Fiona Powrie Journal: J Immunol Date: 2006-11-01 Impact factor: 5.422
Authors: J Rodrigo Mora; Makoto Iwata; Bertus Eksteen; Si-Young Song; Tobias Junt; Balimkiz Senman; Kevin L Otipoby; Aya Yokota; Hajime Takeuchi; Paola Ricciardi-Castagnoli; Klaus Rajewsky; David H Adams; Ulrich H von Andrian Journal: Science Date: 2006-11-17 Impact factor: 47.728
Authors: Katharina Lahl; Christoph Loddenkemper; Cathy Drouin; Jennifer Freyer; Jon Arnason; Gérard Eberl; Alf Hamann; Hermann Wagner; Jochen Huehn; Tim Sparwasser Journal: J Exp Med Date: 2007-01-02 Impact factor: 14.307
Authors: E Israeli; E Goldin; S Fishman; F Konikoff; A Lavy; Y Chowers; E Melzer; A Lahat; M Mahamid; H Shirin; E Nussinson; O Segol; A Ben Ya'acov; Y Shabbat; Y Ilan Journal: Clin Exp Immunol Date: 2015-08 Impact factor: 4.330